Literature DB >> 31186271

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A.

H Marijke van den Berg1, Kathelijn Fischer2, Manuel Carcao3, Hervé Chambost4,5, Gili Kenet6, Karin Kurnik7, Chris Königs8, Christoph Male9, Elena Santagostino10, Rolf Ljung11,12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31186271     DOI： 10.1182/blood.2019000658

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

Review 1.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

2.  Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.

Authors:  Ahmad Faisal Karim; Anthony R Soltis; Gauthaman Sukumar; Christoph Königs; Nadia P Ewing; Clifton L Dalgard; Matthew D Wilkerson; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

3.  Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study.

Authors:  Carla J Jonker; Katrien Oude Rengerink; Arno W Hoes; Peter G M Mol; H Marijke van den Berg
Journal:  Haemophilia       Date:  2020-07-06       Impact factor: 4.287

4.  Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.

Authors:  Brian R Long; Philippe Veron; Klaudia Kuranda; Romain Hardet; Nina Mitchell; Gregory M Hayes; Wing Yen Wong; Kelly Lau; Mingjin Li; M Benjamin Hock; Stephen J Zoog; Christian Vettermann; Federico Mingozzi; Becky Schweighardt
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454

5.  Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates.

Authors:  Victoria E Price; Saunya Dover; Victor S Blanchette; Robert J Klaassen; Mark Belletrutti; Aisha A K Bruce; Anthony K Chan; Cindy Wakefield; Manuel Carcao; Vanessa Bouskill; Nancy L Young
Journal:  Res Pract Thromb Haemost       Date:  2021-03-27

6.  Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients-A Known Issue of Unknown Origin.

Authors:  Christine Keipert; Ursula Drechsel-Bäuerle; Doris Oberle; Mirco Müller-Olling; Anneliese Hilger
Journal:  Int J Environ Res Public Health       Date:  2020-12-30       Impact factor: 3.390

7.  Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.

Authors:  Anouk A M T Donners; Carin M A Rademaker; Lisanne A H Bevers; Alwin D R Huitema; Roger E G Schutgens; Toine C G Egberts; Kathelijn Fischer
Journal:  Clin Pharmacokinet       Date:  2021-08-13       Impact factor: 5.577

8.  Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE).

Authors:  Carmen Escuriola Ettingshausen; Robert F Sidonio
Journal:  Ther Adv Hematol       Date:  2021-09-23

9.  In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.

Authors:  Jeong Pil Han; MinJeong Kim; Beom Seok Choi; Jeong Hyeon Lee; Geon Seong Lee; Michaela Jeong; Yeji Lee; Eun-Ah Kim; Hye-Kyung Oh; Nanyeong Go; Hyerim Lee; Kyu Jun Lee; Un Gi Kim; Jae Young Lee; Seokjoong Kim; Jun Chang; Hyukjin Lee; Dong Woo Song; Su Cheong Yeom
Journal:  Sci Adv       Date:  2022-01-21       Impact factor: 14.136

10.  Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.

Authors:  Ri J Liesner; Aby Abraham; Carmen Altisent; Mark J Belletrutti; Manuel Carcao; Manuela Carvalho; Hervé Chambost; Anthony K C Chan; Leonid Dubey; Jonathan Ducore; Michael Gattens; Paolo Gresele; Yves Gruel; Benoit Guillet; Victor Jimenez-Yuste; Lidija Kitanovski; Anna Klukowska; Sunil Lohade; Maria Elisa Mancuso; Johannes Oldenburg; Anna Pavlova; Berardino Pollio; Marianne Sigaud; Vladimir Vdovin; Kateryna Vilchevska; John K M Wu; Martina Jansen; Larisa Belyanskaya; Olaf Walter; Sigurd Knaub; Ellis J Neufeld
Journal:  Thromb Haemost       Date:  2021-02-13       Impact factor: 5.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.